Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 2, 2011, Pages 267-272

  Bruckert, Eric ^a   Labreuche, Julien ^b,c   Deplanque, Dominique ^b,c,d   Touboul, Pierre Jean ^b,c   Amarenco, Pierre ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

atherogenic dyslipidemia; cardiovascular events; fibrates; HDL cholesterol; meta analysis; triglycerides

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; RISK FACTORS; TRIGLYCERIDES;

EID: 79951552544     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318202709f     Document Type: Review

References (32)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
2. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445. (Pubitemid 44109954)
3. Fruchart JC, Sacks FM, Hermans MP, et al; Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319-335.
4. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.
5. Labreuche J, Deplanque D, Touboul P-J, et al. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis. Systematic review and meta-analysis. Atherosclerosis. 2010:212:9-15.
6. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875- 1884
7. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
8. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122: 962.e1-8.
9. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154: 943-953. (Pubitemid 350001283)
10. Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669-676. (Pubitemid 36343359)
11. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipopro-tein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: 410-418. (Pubitemid 29362514)
12. Robins SJ, Collins D, Wittes JT, et al; VA-HIT Study Group, Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591. (Pubitemid 32240250)
13. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Healthcare. Meta-analysis in Context. 2nd ed. London: BMJ Books; 2001;285-312.
14. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849-1861.
15. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325:1139.
16. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
17. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245 (Pubitemid 17147964)
18. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069-1118.
19. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231: 360-381.
20. Scott R, O'Brien R, Fulcher G, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-498.
21. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37-45.
22. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
23. Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest. 2007;37:925-932. (Pubitemid 350151189)
24. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond). 2008;32(Suppl 2):S11-S16. (Pubitemid 351671296)
25. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-458. (Pubitemid 46184196)
26. Assmann G. Dyslipidaemia and global cardiovascular risk: clinical issues. Eur Heart J. 2006;8(Suppl F):F40-F46. (Pubitemid 44453615)
27. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARal-pha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205:1-8.
28. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298:309-316. (Pubitemid 47080485)
29. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308. (Pubitemid 47080484)
30. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353-361.
31. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6. The Cochrane Library No. 4. Chichester, UK: John Wiley & Sons, Ltd; 2006.
32. Kolovou GD, Anagnostopoulou KK, Damaskos DS, et al. Gender differences in the lipid profile of dyslipidemic subjects. Eur J Intern Med. 2009;20:145-151.